Developer docs
API playgroundTry for free, no card

Search company profiles

SENSIMED

Full company profile

uuid000a17r

Namestring
SENSIMED
Legal namestring
Sensimed S.A.
Websiteurl
sensimed.ch
Company typeenum
Private
Founded yearint
2003
Descriptiontext

SENSIMED S.A. is a Swiss medical device company headquartered in Lausanne that designs, develops, and commercializes the SENSIMED Triggerfish®, a CE-marked and FDA-cleared smart contact lens system for continuous 24-hour ocular monitoring in glaucoma patients. The core product is a soft disposable silicone contact lens embedding a micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, complemented by an adhesive antenna worn around the eye, a portable recorder, and Bluetooth-enabled software that transmits data to the physician's computer for analysis. This represents the first and only technology providing a complete 24-hour picture of ocular dimensional change, including sleep-period data that conventional in-clinic tonometry cannot capture.

The company's revenue model is hardware-based, selling the Triggerfish device and disposable lenses directly to ophthalmologists, glaucoma specialists, and eye care professionals, with a regional distribution partnership through SEED Co., Ltd. for the Japanese and broader Asian market. Sensimed sells through a sales-led motion targeting healthcare providers and reaches clinicians via participation in major ophthalmology conferences (AAO, ESCRS, ARVO, WGC, AGS, EGS), peer-reviewed publications (over 100 cited), and clinical whitepapers. Pricing is not publicly disclosed, and the clinical application requires two appointments (15–30 minutes each) for fitting and removal.

The company was founded in 2003 as a spin-off from EPFL and has accumulated regulatory milestones including CE mark (2010), FDA approval (2016), PMDA registration in Japan (2018), and ISO 13485 / MDSAP certifications. In November 2019, SEED Co., Ltd., a Japanese public contact lens company, acquired over 90% of Sensimed's outstanding shares, making Sensimed a majority-owned subsidiary operating within SEED's smart contact lens strategy. Sensimed employs between 11 and 50 staff and continues to focus on expanding clinical adoption of 24-hour ocular data profiles for personalized glaucoma management.

Short descriptiontext

SENSIMED is a Swiss MedTech company that develops and commercializes the SENSIMED Triggerfish, a smart contact lens system providing 24-hour continuous ocular monitoring for glaucoma management, sold to ophthalmologists and eye care professionals globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
smart contact lens, glaucoma monitoring devices, intraocular pressure monitoring, continuous ocular monitoring, medical device sensors
Industry3 codes
1Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
CodeHLAHAJAIPrimaryYes
2Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
CodeHLAHAJAEPrimaryNo
3Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
CodeHLAHAJACPrimaryNo
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SENSIMED Triggerfish Device Sales
TypeHardware Sales
Description

The company generates revenue through the sale of its SENSIMED Triggerfish contact lens sensor system and disposable lenses, sold to healthcare facilities and ophthalmologists for clinical glaucoma management

sensimed.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SENSIMED Triggerfish®
Description

CE-marked and FDA-approved smart contact lens system for continuous 24-hour ocular monitoring in glaucoma patients. The device includes a disposable silicone contact lens with embedded microsensor, adhesive antenna, portable recorder, and associated software for data analysis.

sensimed.ch
Core offering1 text field

Sensimed designs, develops, and commercializes the SENSIMED Triggerfish, a CE-marked and FDA-approved continuous ocular monitoring system for clinical glaucoma management. The product is a soft disposable silicone contact lens with an embedded micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, paired with an adhesive antenna, a portable recorder, and software that transfers data via Bluetooth for 24-hour continuous monitoring of ocular dimensional changes related to intraocular pressure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 24-hour continuous ocular dimensional change recording including sleep periods
+2 more records
Product overview1 text field

SENSIMED is a Swiss MedTech company offering a single unified product—the SENSIMED Triggerfish® continuous ocular monitoring system. This system comprises three integrated components working together: (1) a soft disposable silicone contact lens with an embedded micro-sensor, (2) an adhesive antenna that wirelessly receives information from the contact lens, and (3) a portable recorder that stores acquired data during the monitoring session, with data transferred via Bluetooth to practitioner software. The product is designed for 24-hour continuous monitoring of ocular dimensional changes to support glaucoma diagnosis and treatment decisions.

Product and service1 record
1SENSIMED Triggerfish®
CategoryOphthalmic medical device for continuous ocular monitoring
Description

A CE-marked and FDA-approved continuous ocular monitoring system consisting of a soft disposable silicone contact lens with an embedded micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, an adhesive antenna worn around the eye, a portable recorder, and Bluetooth-enabled software for physician analysis. Delivers 24-hour monitoring of ocular volume changes related to intraocular pressure for glaucoma specialists managing glaucoma diagnosis, treatment optimization, and identification of patients at risk for faster vision loss.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

SEED and Sensimed built a collaborative alliance since 2013 aimed at getting SENSIMED Triggerfish approved in Japan and capitalizing on the opportunity to spread the product throughout greater Asia.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alcon is a global eye care leader across surgical, vision care, and pharmaceuticals. Comparable as a contact lens/eye care giant with the resources to develop smart contact lens technology and disrupt Sensimed's niche.

TypeEmerging player
Description

Glaukos is a pioneer in MIGS (minimally invasive glaucoma surgery) devices and has expanded into comprehensive glaucoma management. Comparable as a focused glaucoma company addressing unmet needs in glaucoma care, though positioned in surgical rather than diagnostic space.

TypeDirect peer
Description

Reichert is a long-established manufacturer of ophthalmic diagnostic instruments including tonometers and corneal measurement devices. Comparable to Sensimed as a specialist ophthalmic diagnostic instrument vendor serving eye care professionals.

TypeBroad incumbent
Description

Nidek is a Japanese ophthalmic equipment manufacturer offering diagnostic, refractive, and surgical devices. Comparable as a broad incumbent serving the same ophthalmologist customer base, particularly relevant given Sensimed's Japanese ownership under SEED.

TypeDirect peer
Description

iCare is a leading manufacturer of tonometers for intraocular pressure measurement, including rebound self-tonometry for home use. Directly comparable to Sensimed as both target the glaucoma diagnostic workflow, though iCare focuses on spot IOP measurements while Sensimed targets continuous monitoring.

TypeBroad incumbent
Description

Bausch + Lomb is a major contact lens and ophthalmic pharmaceutical manufacturer. Comparable as a contact lens manufacturer with ophthalmic franchise scale that could pursue smart contact lens opportunities similar to Sensimed's technology.

TypeDirect peer
Description

Heidelberg Engineering specializes in ophthalmic diagnostic imaging (OCT, confocal laser imaging) widely used in glaucoma management. Comparable as a specialist diagnostic device vendor serving the same ophthalmology and glaucoma specialist customer base.

TypeBroad incumbent
Description

Carl Zeiss Meditec is a global leader in ophthalmic devices including diagnostic imaging, surgical microscopes, and IOLs. Comparable as a broad incumbent in ophthalmic diagnostics with the resources to bundle continuous monitoring into broader glaucoma workflows.

TypeBroad incumbent
Description

Topcon is a major ophthalmic device manufacturer offering diagnostic imaging, refraction, and surgical equipment. Comparable as a broad incumbent serving ophthalmology practices with comprehensive diagnostic portfolios.

TypeEmerging player
Description

Smartlens is an early-stage company developing smart contact lens technology for non-invasive health monitoring. Comparable as an emerging smart contact lens player with overlapping technological approach and potential future competition in continuous ocular monitoring.

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SENSIMED

Ophthalmic Medical Devicessensimed.ch

SENSIMED is a Swiss MedTech company that develops and commercializes the SENSIMED Triggerfish, a smart contact lens system providing 24-hour continuous ocular monitoring for glaucoma management, sold to ophthalmologists and eye care professionals globally.

What SENSIMED does

SENSIMED S.A. is a Swiss medical device company headquartered in Lausanne that designs, develops, and commercializes the SENSIMED Triggerfish®, a CE-marked and FDA-cleared smart contact lens system for continuous 24-hour ocular monitoring in glaucoma patients. The core product is a soft disposable silicone contact lens embedding a micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, complemented by an adhesive antenna worn around the eye, a portable recorder, and Bluetooth-enabled software that transmits data to the physician's computer for analysis. This represents the first and only technology providing a complete 24-hour picture of ocular dimensional change, including sleep-period data that conventional in-clinic tonometry cannot capture.

The company's revenue model is hardware-based, selling the Triggerfish device and disposable lenses directly to ophthalmologists, glaucoma specialists, and eye care professionals, with a regional distribution partnership through SEED Co., Ltd. for the Japanese and broader Asian market. Sensimed sells through a sales-led motion targeting healthcare providers and reaches clinicians via participation in major ophthalmology conferences (AAO, ESCRS, ARVO, WGC, AGS, EGS), peer-reviewed publications (over 100 cited), and clinical whitepapers. Pricing is not publicly disclosed, and the clinical application requires two appointments (15–30 minutes each) for fitting and removal.

The company was founded in 2003 as a spin-off from EPFL and has accumulated regulatory milestones including CE mark (2010), FDA approval (2016), PMDA registration in Japan (2018), and ISO 13485 / MDSAP certifications. In November 2019, SEED Co., Ltd., a Japanese public contact lens company, acquired over 90% of Sensimed's outstanding shares, making Sensimed a majority-owned subsidiary operating within SEED's smart contact lens strategy. Sensimed employs between 11 and 50 staff and continues to focus on expanding clinical adoption of 24-hour ocular data profiles for personalized glaucoma management.

SENSIMED firmographics

Firmographics
Name
SENSIMED
Legal name
Sensimed S.A.
Website
https://sensimed.ch
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
SENSIMED is a Swiss MedTech company that develops and commercializes the SENSIMED Triggerfish, a smart contact lens system providing 24-hour continuous ocular monitoring for glaucoma management, sold to ophthalmologists and eye care professionals globally.
Ownership category
akta.pro rank

SENSIMED industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro primary industry
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
akta.pro secondary industries
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

  • Smart contact lens
  • Glaucoma monitoring devices
  • Intraocular pressure monitoring
  • Continuous ocular monitoring
  • Medical device sensors

Where SENSIMED is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

SENSIMED business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. SENSIMED Triggerfish Device Sales: The company generates revenue through the sale of its SENSIMED Triggerfish contact lens sensor system and disposable lenses, sold to healthcare facilities and ophthalmologists for clinical glaucoma management

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

SENSIMED product offering

Product offering

Core offering

Sensimed designs, develops, and commercializes the SENSIMED Triggerfish, a CE-marked and FDA-approved continuous ocular monitoring system for clinical glaucoma management. The product is a soft disposable silicone contact lens with an embedded micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, paired with an adhesive antenna, a portable recorder, and software that transfers data via Bluetooth for 24-hour continuous monitoring of ocular dimensional changes related to intraocular pressure.

Product overview

SENSIMED is a Swiss MedTech company offering a single unified product—the SENSIMED Triggerfish® continuous ocular monitoring system. This system comprises three integrated components working together: (1) a soft disposable silicone contact lens with an embedded micro-sensor, (2) an adhesive antenna that wirelessly receives information from the contact lens, and (3) a portable recorder that stores acquired data during the monitoring session, with data transferred via Bluetooth to practitioner software. The product is designed for 24-hour continuous monitoring of ocular dimensional changes to support glaucoma diagnosis and treatment decisions.

Differentiator

Problem solved

Functional benefit

Brands

  • SENSIMED Triggerfish®: CE-marked and FDA-approved smart contact lens system for continuous 24-hour ocular monitoring in glaucoma patients. The device includes a disposable silicone contact lens with embedded microsensor, adhesive antenna, portable recorder, and associated software for data analysis.

Products and services

  • SENSIMED Triggerfish® A CE-marked and FDA-approved continuous ocular monitoring system consisting of a soft disposable silicone contact lens with an embedded micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, an adhesive antenna worn around the eye, a portable recorder, and Bluetooth-enabled software for physician analysis. Delivers 24-hour monitoring of ocular volume changes related to intraocular pressure for glaucoma specialists managing glaucoma diagnosis, treatment optimization, and identification of patients at risk for faster vision loss.

Quantifiable outcome

  • 24-hour continuous ocular dimensional change recording including sleep periods
  • +2 more outcomes

Companies that use SENSIMED

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

SENSIMED technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SENSIMED partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SEED Co., Ltd.coreStrategic or Co-development Partner · 1 January 2013SEED and Sensimed built a collaborative alliance since 2013 aimed at getting SENSIMED Triggerfish approved in Japan and capitalizing on the opportunity to spread the product throughout greater Asia.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

SENSIMED competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Alcon is a global eye care leader across surgical, vision care, and pharmaceuticals. Comparable as a contact lens/eye care giant with the resources to develop smart contact lens technology and disrupt Sensimed's niche.
  • Nidek Co., Ltd. Nidek is a Japanese ophthalmic equipment manufacturer offering diagnostic, refractive, and surgical devices. Comparable as a broad incumbent serving the same ophthalmologist customer base, particularly relevant given Sensimed's Japanese ownership under SEED.
  • Bausch + Lomb: Bausch + Lomb is a major contact lens and ophthalmic pharmaceutical manufacturer. Comparable as a contact lens manufacturer with ophthalmic franchise scale that could pursue smart contact lens opportunities similar to Sensimed's technology.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic devices including diagnostic imaging, surgical microscopes, and IOLs. Comparable as a broad incumbent in ophthalmic diagnostics with the resources to bundle continuous monitoring into broader glaucoma workflows.
  • Topcon Healthcare: Topcon is a major ophthalmic device manufacturer offering diagnostic imaging, refraction, and surgical equipment. Comparable as a broad incumbent serving ophthalmology practices with comprehensive diagnostic portfolios.

Emerging players

  • Glaukos Corporation: Glaukos is a pioneer in MIGS (minimally invasive glaucoma surgery) devices and has expanded into comprehensive glaucoma management. Comparable as a focused glaucoma company addressing unmet needs in glaucoma care, though positioned in surgical rather than diagnostic space.
  • Smartlens: Smartlens is an early-stage company developing smart contact lens technology for non-invasive health monitoring. Comparable as an emerging smart contact lens player with overlapping technological approach and potential future competition in continuous ocular monitoring.

Direct peers

  • Reichert Technologies: Reichert is a long-established manufacturer of ophthalmic diagnostic instruments including tonometers and corneal measurement devices. Comparable to Sensimed as a specialist ophthalmic diagnostic instrument vendor serving eye care professionals.
  • iCare (Revenio Group): iCare is a leading manufacturer of tonometers for intraocular pressure measurement, including rebound self-tonometry for home use. Directly comparable to Sensimed as both target the glaucoma diagnostic workflow, though iCare focuses on spot IOP measurements while Sensimed targets continuous monitoring.
  • Heidelberg Engineering: Heidelberg Engineering specializes in ophthalmic diagnostic imaging (OCT, confocal laser imaging) widely used in glaucoma management. Comparable as a specialist diagnostic device vendor serving the same ophthalmology and glaucoma specialist customer base.

Market position

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

SENSIMED social profiles

Digital presence

SENSIMED compliance and trust

Trust signal

Compliance5 records

SENSIMED financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SENSIMED leadership team

Management profile

Number of profiles

Profiles6 records

SENSIMED funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SENSIMED M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SENSIMED

What does SENSIMED do?

Sensimed designs, develops, and commercializes the SENSIMED Triggerfish, a CE-marked and FDA-approved continuous ocular monitoring system for clinical glaucoma management. The product is a soft disposable silicone contact lens with an embedded micro-sensor that captures spontaneous circumferential changes at the corneoscleral area, paired with an adhesive antenna, a portable recorder, and software that transfers data via Bluetooth for 24-hour continuous monitoring of ocular dimensional changes related to intraocular pressure.

Is SENSIMED a public or private company?

SENSIMED is a private company. It is classified as corporate owned and is currently operating.

When was SENSIMED founded?

SENSIMED was founded in 2003. It employs 11 to 50 people.

Where is SENSIMED based?

SENSIMED is headquartered in Lausanne, Switzerland, in the Europe region.

How does SENSIMED make money?

One revenue line is on record: SENSIMED Triggerfish Device Sales.

Who are SENSIMED's main competitors?

Broad incumbents on record are Alcon, Nidek Co., Ltd., Bausch + Lomb, Carl Zeiss Meditec and Topcon Healthcare. Emerging players are Glaukos Corporation and Smartlens. Direct peers are Reichert Technologies, iCare (Revenio Group) and Heidelberg Engineering.

Does SENSIMED have an API?

No public API is recorded for SENSIMED.

What industry is SENSIMED in?

SENSIMED's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions). Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSmart Contact Lenses Market Growth Rate Analysis at 23.5% CAGR by 2032 | Sensimed AG, Samsung, Sony, XPANCEOQY Research Inc. released a market report forecasting the global smart contact lenses market to grow from US$ 516 million in 2025 to US$ 2,222 million by 2032, representing a 23.5% CAGR. The analysis highlights key industry players including Sensimed AG, Samsung, Sony, and XPANCEO, alongside technological developments in biosensing and AR displays. The report details regional growth opportunities and regulatory landscapes across North America, Europe, Asia Pacific, and other regions.FortunebusinessinsightsSmart Contact Lenses Market Size, Share, TrendsA market report projects the global smart contact lenses market to grow from USD 115.0 million in 2018 to USD 9,725.5 million by 2032, driven by rising prevalence of diabetes and glaucoma. Key industry players such as Google, Samsung, and Sensimed are actively developing these wearable technologies for medical diagnostics and vision enhancement. Strategic alliances and increased R&D spending are identified as primary factors accelerating market expansion across North America and other regions.CairnsSmart Contact Lenses: The Future of Vision & Health TechXPANCEO and Sensimed are developing smart contact lenses that integrate biosensors to monitor intraocular pressure and detect biomarkers in tear fluid for early diagnosis of conditions like glaucoma and diabetes. These devices aim to transform vision care by providing continuous physiological data, targeted drug delivery, and augmented reality interfaces while overcoming challenges related to power supply and regulatory approval.AaoSmart Lens Helps Predict ProgressionResearchers at Columbia University Medical School have developed a smart contact lens, the Sensimed Triggerfish, which monitors intraocular pressure (IOP) patterns over 24 hours, aiding in the management of glaucoma. This technology allows for better prediction of glaucoma progression than traditional methods through continuous monitoring during patients' daily routines. The lens has received FDA approval and is expected to transform IOP monitoring in ophthalmology.PR NewswireSmart Contact Lens Helps Predict Disease Progression in Glaucoma PatientsResearchers at Columbia University Medical Center conducted a two-year study, published in Ophthalmology journal, testing Sensimed Triggerfish smart contact lenses on 40 glaucoma patients to monitor eye pressure continuously over 24 hours. The study found that specific electrical signal patterns from the lenses, particularly steeper overnight spikes and a greater number of peaks, correlated with faster glaucoma progression compared to traditional single-point eye pressure measurements. The Sensimed Triggerfish device is currently approved in Europe but lacks U.S. Food and Drug Administration approval.FinSMEsSensimed Raises CHF17M in First Close of Series C FundingSensimed AG raised CHF17M in its first Series C funding round, co-led by Wellington Partners, Agate Medical Investments, and Vinci Capital. The company will use the capital to finalize US and China approvals, expand commercialization beyond about twenty countries, and fund ongoing operations.VC News DailySensimed AG Raises Series CSensimed AG announced the first closing of its Series C financing round, raising CHF 17 million in co-led investments from Wellington Partners, Agate Medical Investments, and Vinci Capital/Renaissance PME. The company plans to use the funds to secure regulatory approvals in the US and China, expand its commercialization beyond current markets, and continue post-marketing trials for its SENSIMED Triggerfish glaucoma management device.FinSMEsSensimed Raises Additional CHF3.5M in Series B FinancingSensimed raised CHF3.5M in a Series B financing round, with existing investors including Wellington Partners, Vinci Capital, and BlueOcean Ventures. The funds will support US and Asian regulatory approvals, commercialization, post-marketing trials, and operations.